All AbMole products are for research use only, cannot be used for human consumption.
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC).
U251 Cell Line were stained with Lorvotuzumab-MMAE and negative control protein respectively, washed and then followed by PE and analyzed with FACS, the EC50 is 0.02 μg/mL.
The drug-to-antibody ratio (DAR) of the Lorvotuzumab-MMAE is 4.1.
| Molecular Weight | 145000 |
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
| Praluzatamab-MMAE
Praluzatamab-MMAE is an antibody-drug conjugate (ADC). |
| Oregovomab-MMAE
Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
| Patritumab-MMAE
Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE. |
| Depatuxizumab mafodotin
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
